# CRF2 Agonist for the Treatment of Worsening Heart Failure

> **NCT06815471** · PHASE2 · RECRUITING · sponsor: **Corteria Pharmaceuticals** · enrollment: 300 (estimated)

## Conditions studied

- Worsening Heart Failure

## Interventions

- **DRUG:** COR-1167
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06815471
- **Lead sponsor:** Corteria Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-07
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06815471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06815471, "CRF2 Agonist for the Treatment of Worsening Heart Failure". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT06815471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*